[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100597284":3},{"organization":4,"armGroups":7,"interventions":8,"overallOfficials":7,"centralContacts":12,"locations":21,"responsibleParty":36,"collaborators":7,"id":38,"slug":39,"hasResults":40,"nctId":41,"briefTitle":42,"officialTitle":43,"acronym":44,"eligibilityCriteria":45,"healthyVolunteers":40,"sex":46,"minAge":47,"maxAge":7,"enrollmentInfo":48,"targetDuration":7,"studyType":51,"phases":7,"briefSummary":52,"conditions":53,"keywords":7,"overallStatus":55,"whyStopped":7,"lastUpdateSubmitDate":56,"lastUpdatePostDateStruct":57,"startDateStruct":60,"completionDateStruct":62,"leadSponsor":64,"locationsCount":65},{"fullName":5,"class":6},"RenJi Hospital","OTHER",null,[9],{"type":6,"name":10,"description":11,"armGroupLabels":7,"otherNames":7},"mRNA level of REST4 in serum;","1. mRNA level of REST4 in serum The mRNA expression level of REST4 was measured in serum-derived exosomes using RT-qPCR at the time of patient enrollment.\n2. Computed tomography angiography (CTA) Baseline maximum internal diameter of the abdominal aortic aneurysm (AAA) was determined by CTA at enrollment. During follow-up, CTA was performed to assess the increase in maximum AAA diameter.",[13,18],{"name":14,"role":15,"phone":16,"phoneExt":7,"email":17},"Jun Pu, MD,PhD","CONTACT","86-21-68383477","pujun310@hotmail.com",{"name":19,"role":15,"phone":16,"phoneExt":7,"email":20},"Yinan Li, MD,PhD","liyinan0402@126.com",[22],{"facility":23,"status":7,"city":24,"state":25,"zip":7,"country":26,"countryCode":27,"cosmosGeoPoint":28,"geoPoint":33,"contacts":34},"Ren Ji Hospital Afflited to School of Medicine, Shanghai Jiao Tong University","Shanghai","Shanghai Municipality","China","CN",{"type":29,"coordinates":30},"Point",[31,32],121.45806,31.22222,{"lat":32,"lon":31},[35],{"name":14,"role":15,"phone":16,"phoneExt":7,"email":17},{"type":37,"investigatorFullName":7,"investigatorTitle":7,"investigatorAffiliation":7,"oldNameTitle":7,"oldOrganization":7},"SPONSOR","100597284","rest4-aaa-registry-100597284",false,"NCT07056491","REST4-AAA Registry","Serum REST4 as a Predictive Biomarker for Abdominal Aortic Aneurysm Progression","REST4 Registry","Inclusion Criteria:\n\n1. Presence of an infrarenal AAA with a maximum diameter of 39-49 mm;\n2. Han nationality;\n3. Between 50 years or more, no gender limit;\n4. No mental illness;\n5. Subjects voluntarily participate in this study, sign an informed consent form, have good compliance, and cooperate with follow-up.\n\nExclusion Criteria:\n\n1. Previous infrarenal aortic surgery;\n2. Planned major surgery;\n3. Known aortic dissection;\n4. Have received any other clinical trial treatment within 1 year;\n5. Systemic treatment with corticosteroids or other systemic immunomodulatory therapy;\n6. Severe infections, including but not limited to infections requiring hospitalization, bacteremia, severe pneumonia, etc.;\n7. Known or suspected inherited connective tissue disorder;\n8. Known or suspected prostate cancer;\n9. Calculated creatinine clearance of less than 30 ml\u002Fmin;\n10. Known significant liver disease;\n11. Known human immunodeficiency virus infection at the time of screening；\n12. Serious concomitant illness associated with life expectancy of less than 2 years；\n13. Any other significant and unstable condition that could limit compliance with the trial protocol.","ALL","18 Years",{"count":49,"type":50},70,"ESTIMATED","OBSERVATIONAL","This prospective observational study aims to investigate whether serum REST4 concentration can serve as a quantitative indicator correlated with abdominal aortic aneurysm (AAA) diameter and a predictive biomarker for AAA progression and rupture risk. Emerging evidence suggests that REST4, a splice variant of the RE-1 Silencing Transcription Factor (REST), is upregulated in vascular smooth muscle cells during AAA pathogenesis and may be released into circulation via exosomes. The study will enroll patients with asymptomatic AAA (diameter between 39-49 mm) and measure baseline serum REST4 levels, analyzing their association with morphological severity (maximum aortic diameter) and clinical outcomes (aneurysm growth rate, rupture and related mortality) through a 5-year follow-up period.",[54],"Abdominal Aortic Aneurysm","NOT_YET_RECRUITING","2025-06-29",{"date":58,"type":59},"2025-07-09","ACTUAL",{"date":61,"type":50},"2025-07-01",{"date":63,"type":50},"2031-07-01",{"name":5,"class":6},1]